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Rap1Altered Ras superfamily guanine nucleotide triphosphatase signaling may contribute to the activation of
autoreactive T cells in diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here, we
show that transgenic expression of activated Rap1, a Ras-related protein which is protective in murine arthritis,
in both wildtype (WT) and 2D2 mice, enhances autoreactive T cell activation by myelin oligodendrocyte glycopro-
tein peptide in vitro and in vivo. However, RapV12 reduces the number of autoreactive T cells in bothWT and 2D2
mice, and increases murine survival in experimental autoimmune encephalitis, suggesting Rap1 activation restricts
autoimmune T cell-mediated pathology through enhancing tolerance.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
T cells speciﬁc for self-antigens have been proposed to play a pivotal
role in many autoimmune diseases. This pathogenic concept relies on
several lines of evidence. Firstly, genetic analysis revealed an association
of several autoimmune diseases with MHC class II molecules, such as
HLA-DR4 in rheumatoid arthritis (RA), as well as with other molecules
involved in T cell activation or T cell receptor (TCR) signaling. As a proto-
typical example, genetic polymorphisms in PTPN22, a critical inhibitor in
T cell receptor signaling, are associated with susceptibility to RA, type 1
diabetes (T1D), and systemic lupus erythematosus (SLE) (Gregersen,
2005). Secondly, clonally expanded CD4+ T cell populations are present
in the primary target tissues or draining lymph nodes (LN) in autoim-
mune diseases such as RA and T1D (Kent et al., 2005; Cantaert et al.,
2009). Thirdly, functional analyses have demonstrated critical contribu-
tions of autoreactive T cells to pathology in several animal disease
models. In the NOD mouse, CD4+ T cells are essential both in the early
and late stages of T1D and directly contribute to the destruction ofnology and Rheumatology, Ac-
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evier OA license.pancreatic β-cells (Anderson and Bluestone, 2005). In experimental au-
toimmune encephalomyelitis (EAE), severe central nervous system dam-
age is caused by the activation of myelin-speciﬁc T cells as evidenced by
TCR transgenic models and transfer experiments with pathogenic T cells
(Kuchroo et al., 2002). In collagen-induced arthritis (CIA), effector CD4 T
cells produce pro-inﬂammatory cytokines and stimulate B cells to pro-
duce anti-collagen type II antibodies critical to the promotion of patholo-
gy (Brand et al., 2003). Fourthly, the use of T cell targeted therapies has
proven efﬁcacy in several human autoimmune diseases, including the
targeting of effector T cells with alefacept in psoriasis (Ellis and Krueger,
2001), costimulation blockade with CTLA4-Ig in RA (Kremer et al.,
2003), and anti-CD3 therapy in T1D (Keymeulen et al., 2005).
Recent research has focused on the identiﬁcation of speciﬁc intracel-
lular signaling pathways that control the development, expansion, and
activation of autoreactive T cells as these pathways may form attractive
candidates for therapeutic modulation in autoimmune disease. Mem-
bers of the Ras superfamily of small guanine nucleotide triphosphatases
(GTPases), particularly Ras and Rap1 GTPases, have emerged as key
candidates. Activation of both Ras and Rap1 GTPases in T lymphocytes
ismediated by their binding toGTP following TCR ligation or chemokine
stimulation (Genot and Cantrell, 2000; Minato et al., 2007) and alter-
ations in these signaling pathways have been linked to autoimmune
disease. For example, partial inactivation of T cell Ras, as observed in
mice deﬁcient for RasGRP1, a guanine nucleotide exchange factor
(GEF) which couples TCR ligation to Ras activation, results in spontane-
ous SLE-like pathology (Layer et al., 2003). This is not due to overall T
cell hyperreactivity, as peripheral T cell numbers and proliferative re-
sponses are reduced in these mice, but rather to inefﬁcient negative
36 G.F. Salinas et al. / Journal of Neuroimmunology 250 (2012) 35–43selection of autoreactive T cells by self-antigen in the thymus (Layer
et al., 2003; Priatel et al., 2006, 2007). Strikingly, Ras-dependent T cell
signaling and proliferative responses are suppressed in SLE patient
peripheral blood T cells, associated with decreased expression and
function of Ras GEFs (Cedeno et al., 2003; Yasuda et al., 2007).
A potential role for Rap1 in human T cell-mediated autoimmune dis-
easewas ﬁrst suggested by the fact that Rap1 is inactivated in RA synovi-
alﬂuid T cells and that this is associatedwith the persistent production of
reactive oxygen species (ROS) and hyper-responsive cytokine produc-
tion following TCR triggering (Remans et al., 2004, 2006; Abreu et al.,
2009). Similarly to Ras, Rap1 is activated by TCR and adhesion molecule
ligation, as well as by chemokine stimulation (Minato et al., 2007). Once
activated, Rap1 orchestrates the assembly of adaptor proteins and activa-
tion of downstreamkinases needed for integrin-mediated trafﬁcking of T
cells to lymphoid organs and their adhesion to antigen presenting cells
(APCs). In mice, genetic inactivation of T cell Rap1 leads to an age-
dependent accumulation of activated T cells in peripheral lymphoid or-
gans (Dillon et al., 2005). Conversely, constitutive activation of T cell
Rap1 results in age-dependent hyporesponsiveness to antigenic chal-
lenge (Ishida et al., 2003; Li et al., 2005). Constitutive activation of
Rap1 can also antagonize Ras-dependent mitogen-activated protein ki-
nase (MAPK) activation, likely via indirect effects of Rap1 on T cell ROS
production (Boussiotis et al., 1997; Bos et al., 2001; Remans et al., 2004).
To directly assess the impact of T cell Rap 1 signaling on autoim-
munity, we recently examined mice expressing a hypermorphic mu-
tant of Rap1A (RapV12) in the T cell compartment and found that
these mice were protected from CIA (Sebzda et al., 2002; Abreu et
al., 2010). Protection against pathology in this model was associated
with speciﬁc in vivo defects in TNFα production by CD8+ LN T cells
during arthritis onset, and a failure of RapV12 mice to generate high
titers of anti-collagen antibodies. However, furthermechanistic insight
as to how sustained T cell Rap1 activation protected mice against auto-
immunity in CIA was hampered by the inability to track the activation
and fate of autoantigen-speciﬁc T cells in this model. In the present
study,we examined the role of T cell Rap1 activation inmyelin oligoden-
drocyte glycoprotein (MOG)-induced EAE, an autoimmune disease me-
diated by pathogenic autoreactive T cells without major contribution of
autoantibodies. In this model, speciﬁc auto-reactive T cells can be stud-
ied using a transgenic 2D2 mouse in which all T lymphocytes bear
TCRs speciﬁc for the immunodominant epitopeMOG and can be tracked
by their TCR β-chain Vβ11 (Bettelli et al., 2003). Auto-reactive T cells can
also be studiedwith tetramer staining ofMOG-speciﬁc TCRs (Sabatino et
al., 2011). Taking advantage of these features, we ﬁrst studied the effect
of sustained Rap1 activation on the quality of the autoreactive T cell re-
sponse in terms of proliferation, activation and cytokine production.
Subsequently, we analyzed the quantitative effects on the size of the
autoreactive T cell pool. Finally, we assessed whether the qualitative
and quantitative effects translated in attenuation of clinical disease.2. Materials and methods
2.1. Animals
Transgenic C57BL/6 J mice expressing hypermorphic RapV12 under
the control of the CD2 promoter were provided by Dr. D.A. Cantrell
(University of Dundee, Dundee, UK) (Sebzda et al., 2002). 2D2 trans-
genic C57BL/6 Jmicewere provided byDr. V. Kuchroo (HarvardMedical
School, Boston, MA, USA) (Bettelli et al., 2003). RapV12 transgenic ani-
mals were crossed with 2D2 mice and the F1 generation of 2D2+
RapV12- and 2D2+RapV12+ were used for EAE experiments. All ani-
mals were housed under conventional conditions in the animal facility
of the AcademicMedical Center/University of Amsterdam (Amsterdam,
The Netherlands). All experiments were performed according to local
regulations and were approved by the Animal Ethics Committee of the
Academic Medical Center/University of Amsterdam.2.2. Induction and assessment of EAE
Mice (8–12 weeks of age) were immunized subcutaneously in two
sites of the neck on day 0 with 100 μg of MOG peptide (amino acid
residues 35–55, sequence MEVGWYRSPFSRVVHLYRNGK) (AnaSpec,
Freemont CA, USA) emulsiﬁed in complete Freund's adjuvant (CFA)
(Chondrex, Bellevue WA, USA) supplemented with 400 μg/ml of
M. tuberculosis (Difco Laboratories, Sparks MD, USA). Additionally,
mice were injected intravenously on days 0 and 2 with 150 ng of per-
tussis toxin (Sigma-Aldrich, St. Louis MI, USA). Following immuniza-
tion, the animals were scored 3 times per week until onset of EAE.
After onset of clinical EAE, scoring was performed daily until day 30
after immunization. A 5-point scale was used to evaluate signs of
neurological disease: 0, no disease; 1, decreased tail tone; 2, hind-
limb weakness or partial paralysis; 3, complete hind-limb paralysis;
4, front and hind limb paralysis. Mice that reached a score of 4 were
euthanized immediately for ethical reasons.
2.3. Flow cytometric detection of surface proteins
Spleen and LN were collected from non-immunized mice and from
animals 10 days after immunization with MOG. Single-cell suspensions
were obtained, erythrocytes removed, and cells were then stained at
4 °Cwith the indicatedﬂuorochrome-conjugated anti-mousemonoclonal
antibodies for surface markers or with isotype- and concentration-
matched control antibodies. Antibodies used in this study included
Alexa700-conjugated anti-CD3, Alexa700-conjugated anti-CD4, phycoer-
ythrin (PE)-Cy7-conjugated anti-CD4, Alexa 780-conjugated anti-CD8,
PE-conjugated anti-vβ11, FITC-conjugated anti-CD44 and PerCP-Cy5.5-
conjugated anti-CD62L (eBioscience CA, San Diego, USA). For tetramer
staining of MOG-reactive T cells, CD4 T cells were puriﬁed using an anti-
CD4 antibody and LS columns (Miltenyi Biotech GmbH., Bergisch
Gladbach, Germany) according to manufacturer's instructions. CD4+ T
cells were incubated overnight with 4 μg/ml of MOG38–49IAb or negative
control hCLIP103–117 IAb tetramers (Sabatino et al., 2008, 2011). Flow
cytometric analysis was performed and analyzed using a 7-color FACS
Canto (BD Biosciences, San Jose CA, USA) and FlowJo software (Tree Star
Inc., Ashland OR, USA). The results were expressed as % of positive cells.
2.4. T cell stimulation and detection of costimulatory molecules, cytokine
production and proliferation
Todetect the expression of costimulatorymolecules and the produc-
tion of intracellular cytokines, 4×106 cells/ml in RPMI supplemented
with 10% FCS, β-mercaptoethanol, L-glutamine, gentamicin sulfate
and penicillin/streptomycin, were stimulated in 96-well plates for 6 h
with phorbol myristate acetate (PMA, 10 ng/ml; Sigma-Aldrich) and
ionomycin (1 μM; Sigma-Aldrich). Alternatively cells were cultured
with medium alone or medium supplemented with MOG peptide
(3 or 10 μg/ml) or anti-CD3 (5 μg/ml) and anti-CD28 antibodies
(5 μg/ml) (both provided by Dr. L. Boon, Bioceros BV, Utrecht, NL)
for 24 or 48 h. For the detection of intracellular cytokines, Brefeldin
A (5 μg/ml; Sigma-Aldrich) was added for the last 4 h of culture,
and cells were ﬁxed and permeabilized using a BD intracellular
staining kit (BD BioSciences). Cells were stained with FITC-conjugated
PD-1, PE-conjugated ICOS, APC-conjugated CD40L, Alexa 488-
conjugated anti-IL-17, PerCP-Cy5.5-conjugated anti-IFN-γ, PE-Cy7-
conjugated anti-IL-2, and APC-conjugated anti-TNFα (eBiosciences,
San Diego, USA). To assess proliferative capacity, cells were labeled
with carboxyﬂuorescein succinimidyl ester (CFSE, 1 μg/ml; Molecular
Probes, Eugene OR, USA) and subsequently stimulated for 72 h in the
absence or presence of MOG peptide or anti-CD3/CD28 antibodies.
Cells were then analyzed for CFSE dilution, mean number of cell divi-
sions and precursor frequency by ﬂow cytometry. Staining with
7-aminoactinomycin D (BD Biosciences) was used to exclude dead
cells. The results were expressed as percentage of positive cells or as
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ched isotype control.
2.5. Statistics
Numerical data were depicted in a box plot and the variation was
described by median and interquartile range (IQR). Gehan–Breslow–
Wilcoxon test was used to compare the incidence of EAE and the sur-
vival proportions between groups of mice. The severity of EAE per
group was assessed by calculating the area under the curve for each
mouse in the group, and groups were compared using a Mann–
Whitney non-parametrical t-test. Flow cytometric data were com-
pared using Mann–Whitney non-parametrical t-test. P-values≤0.05
were considered statistically signiﬁcant.
3. Results
3.1. Sustained Rap1 activation promotes autoreactive T cell
hyperresponsiveness
Previous reports indicated that Rap1-GTP levels are elevated in
anergic T cells and that T cell Rap1 activation can dampen antigen-
speciﬁc proliferation (Boussiotis et al., 1997; Sebzda et al., 2002). In
order to determine whether similar effects are observed in MOG-
speciﬁc T lymphocytes, we recovered autoreactive T cells (Bettelli
et al., 2003) from the spleens of 2D2+RapV12+ and 2D2+RapV12-
animals, stimulated these cells in vitro, and determined their capac-
ity to proliferate, produce IL-2, and upregulate the expression of
costimulatory molecules. Autoreactive Vβ11+CD4+ T cells recovered
from naïve 2D2+RapV12+mice proliferated more than their counter-
parts from 2D2+RapV12- animals, both upon non-speciﬁc stimulation
with anti-CD3/CD28 (p=0.017) and upon MOG peptide stimulation
(p=0.004 and p=0.030 for 1 μg/ml and 3 μg/ml MOG, respectively)
(Fig. 1A). Conﬁrming that the RapV12 mutant did not induce anergy ofFig. 1. Autoreactive T cells are hyperresponsive, not anergic in RapV12 mice. Splenocytes fro
cultured with medium, anti-CD3/CD28 antibodies and MOG peptide. After 3 days, the percen
culated by CFSE dilution. Splenocytes from 2D2+RapV12- and 2D2+RapV12+ naïve mic
24–48 h. The percentages of Vβ11+CD4+ (B, C) and Vβ11-CD4+ (E, F) T lymphocytes
Mann–Whitney test was used to compare groups (*p-value≤0.05).autoreactive T cells, IL-2 production was maintained upon anti-CD3/
CD28 stimulation and even increased upon MOG stimulation (p=
0.044 with 3 μg/ml) (Fig. 1B). Also ICOS expression was increased upon
MOG stimulation (p=0.004 with 3 μg/ml and p=0.030 with 10 μg/ml
MOG) (Fig. 1C) in the 2D2+RapV12+ animals. This was speciﬁc for
the autoreactive cells as we noted only a slight but signiﬁcant increase
inMOG-speciﬁc proliferation of Vβ11-CD4+T cells in double transgenic
animals (Fig. 1D), and no differences in IL-2 production (Fig. 1E) or ICOS
expression (Fig. 1F) between single and double transgenic animals. Ex-
pression levels of other costimulatory molecules such as PD-1 and
CD40L were comparable between 2D2+RapV12- and 2D2+RapV12+
lymphocytes (data not shown). Similar experiments with T cells
recovered from animals 10 days after immunization with MOG to
mimic recall rather than primary responses, further conﬁrmed these
ﬁndings. Also in this experimental setting, the autoreactive T cells dis-
played signiﬁcantly increased IL-2 production (p=0.008 with anti-
CD3/CD28 stimulation and p=0.036 with 3 μg/ml and 10 μg/ml MOG)
(Fig. 2A) and ICOS expression (p=0.015 with 3 μg/ml and p=0.031
with 10 μg/ml MOG) (Fig. 2B) in the presence of the hypermorphic
RapV12 mutant, while no differences in the responsiveness of Vβ11-
CD4+ T cells were observed (Fig. 2C–D). Taken together, these data
indicate that the autoreactive T cells are not anergic but rather hyper-
responsive in the RapV12 animals.
3.2. Sustained activation of Rap1 does not impair cytokine production by
autoreactive T cells
As CD4+ T lymphocytes producing IFNγ and IL-17 are the main
effector cells contributing to central nervous system inﬂammation
in MOG-induced EAE (Jager et al., 2009; El-behi et al., 2010), we
next assessed whether the increased proliferation and ICOS expres-
sion of the autoreactive T cells in the presence of RapV12 functionally
translated in altered production of pro-inﬂammatory cytokines.
In vitroMOG restimulation of Vβ11+CD4+ T lymphocytes recoveredm naive 2D2+RapV12- and 2D2+RapV12+ mice (A, D) were stained with CFSE and
tages of proliferating Vβ11+CD4+ (A) and Vβ11-CD4+ (D) T lymphocytes were cal-
e were stimulated with medium, anti-CD3/anti-CD28 antibodies and MOG peptide for
producing IL-2 (B, E) or expressing ICOS (C, F) were analyzed by ﬂow cytometry.
Fig. 2. Splenocytes from immunized 2D2+RapV12- and 2D2+RapV12+ mice were stimulated with medium, anti-CD3/anti-CD28 antibodies and MOG peptide for 24–48 h. The
percentages of Vβ11+CD4+ (A, B) and Vβ11-CD4+ (C, D) T cells producing IL-2 (A, C) or expressing ICOS (B, D) were analyzed by ﬂow cytometry. Mann–Whitney test was used
to compare groups (*p-value≤0.05).
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IFNγ expression between 2D2+RapV12- and 2D2+RapV12+ mice
(Fig. 3A and B, respectively). Increased TNFα expression was observed
upon anti-CD3/CD28 stimulation (p=0.056) and lowdoseMOG stimula-
tion (p=0.032 for 3 μg/ml) in the autoreactive T cells recovered from the
2D2+RapV12+ compared to 2D2+RapV12- mice (Fig. 3C). A similar
analysis of vβ11+CD4+T cells fromnaïvemice did not show any differ-
ences between 2D2+RapV12- and 2D2+RapV12+ animals for these
three cytokines (Fig. 3D–F). Conﬁrming the speciﬁcity of these ﬁndings,Fig. 3. Autoreactive T cell cytokine production is not impaired by sustained Rap1 activation. S
tide (A–C) and 2D2+RapV12+ and 2D2+RapV12- naïve animals (D–F), were stimulated w
Vβ11+CD4+ T cells producing IL-17 (A, D), IFNγ (B, E) or TNFα (C, F) were determined b
(*p-value≤0.05).an analysis of the vβ11-CD4+ T cells, which do not bear the MOG-
speciﬁc TCR transgene, did not show any cytokine production at all
upon MOG stimulation in either naïve or immunized 2D2+RapV12-
and 2D2+RapV12+animals (data not shown). Furthermore,we repeat-
ed this experiment using PMA/ionomycin for in vitro restimulation of
vβ11+CD4+ autoreactive T cells that were primed in vivo by MOG im-
munization. In this experimental setting, we observed a trend towards
an increase in the production of IL-17 and similar expression of IFNγ
and TNFα in 2D2+RapV12- and 2D2+RapV12+ animals (data notplenocytes from 2D2+RapV12+ and 2D2+RapV12- mice immunized with MOG pep-
ith medium, anti-CD3/CD28 antibodies and MOG peptide for 24 h. The percentages of
y intracellular staining. Mann–Whitney test was used for comparison between groups
39G.F. Salinas et al. / Journal of Neuroimmunology 250 (2012) 35–43shown). These data indicate that constitutive Rap1 signaling does not
markedly modulate the production of pathogenic cytokines by MOG-
speciﬁc autoreactive T cells in this model.
3.3. Sustained activation of Rap1 does not induce activation-induced cell
death of autoreactive T cells
Based on the reported effects of Ras guanyl-releasing protein 1
(GRP1) defects on thymic selection and autoimmunity (Amsen et al.,
2000; Priatel et al., 2002), we next considered the possibility that Rap1
activationmay affect the size of the autoreactive T cell pool by either pe-
ripheral or central deletion of MOG-reactive T cells. We ﬁrst assessed
whether the increased ex vivo proliferation upon MOG stimulation was
associated with changes in activation-induced cell death (AICD) of
autoreactive T cells in the presence of sustained Rap1 signaling (Green
et al., 2003). As in the previously described proliferation assays, we re-
covered splenic T cells from 2D2+RapV12+ and 2D2+RapV12- mice
and stimulated them in vitrowith MOG peptide for 3 days. The survival
of autoreactive T cells as measured by the percentage of 7-AAD-
negative vβ11+CD4+ T cells was signiﬁcantly increased in the
2D2+RapV12+ samples versus the 2D2+RapV12- controls after stim-
ulation with MOG peptide (p=0.038 with 1 μg/ml and p=0.018 after
stimulation with 3 μg/ml MOG, Fig. 4A). The vβ11-CD4+ population,
which does not express the autoreactive TCR, did not display these
changes in survival (data not shown). Repeating these experiments
with T cells recovered 10 days after in vivo priming with MOG yielded
an increased percentage of livingT cells in 2D2+RapV12+ lymphocytes
when compared to 2D2+RapV12- after stimulation with anti-CD3/
CD28 antibodies (p=0.015, Fig. 4B). In line with the in vitro data, ex
vivo phenotypic analysis of the splenic T cells 10 days after immuniza-
tion with MOG revealed a signiﬁcantly increased accumulation of effec-
tor (p=0.008) and central memory (p=0.055) autoreactive T cells and
a reciprocal decrease of naïve Vβ11+CD4+ T cells (p=0.008) in the
2D2+RapV12+ versus the 2D2+RapV12- animals (Fig. 4C–E). This
difference was speciﬁcally related to the response to MOG priming as
the percentages of naïve, effector, and central memory cells were similar
between the two strains under homeostatic conditions (data notFig. 4. Sustained Rap1 enhances central and effector memory differentiation in the autorea
MOG immunized 2D2+RapV12- and 2D2+RapV12+mice (B) were cultured with medium
non-viable cells within the Vβ11+CD4+ T lymphocyte compartment and subtract them fr
2D2+RapV12+ mice immunized with MOG peptide (C–E) were stained with anti-CD3,
CD44hiCD62L- (C), central memory CD44hiCD62L+ (D) and naive CD44loCD62L+ (E) T cells
The percentages of positive cells were compared using Mann–Whitney test (*p-value≤0.05shown). These in vitro and in vivo data indicate that increased MOG-
induced proliferation of autoreactive T cells in the presence of sustained
Rap1 is not a consequence of changes in AICD.3.4. Sustained activation of Rap1 affects the size of the autoreactive T cell
pool
We next assessed whether the hypermorphic RapV12 mutant may
have quantitative effects on the size of the pool of autoreactive T cells
in 2D2+RapV12+ animals. Analysis of MOG-immunized animals
showed that the frequency of Vβ11+CD4+ T cells in the total
splenocyte population was signiﬁcantly diminished in the 2D2+
RapV12+ versus 2D2+RapV12- animals (medians 11 versus 15%,
p=0.007, Fig. 5A). As the autoreactive T cells form 85% of the total T
cell repertoire in the 2D2 mice, the number of CD3+CD4+ T cells
was equally reduced in the double transgenic animals relative to the
single transgenic controls (medians 14 versus 23%, p=0.03, Fig. 5B).
Accordingly, trends towards reduced numbers of Vβ11+CD4+ and
CD3+CD4+, but not CD8+ or FoxP3+ T cells were observed in
spleens of immunized 2D2+RapV12+mice (Supplemental Fig. 1). Be-
cause our in vitro experiments did not provide evidence for AICD, we
aimed to determine if this effect was due to homeostatic central or
activation-dependent mechanisms by repeating the same experiment
in naïve animals, prior to peripheral exposure to the autoantigen.
Both the percentages of autoreactive Vβ11+CD4+ T cells (medians
15 versus 27% p=0.05) and of total CD4+ T cell (medians 17 versus
30%, p=0.03) were decreased in the spleens of the naïve 2D2+
RapV12+ versus 2D2+RapV12- animals (Fig. 5C–D), as were the
total numbers of these cell populations (Supplemental Fig. 2). To assure
that this was a reproducible effect of Rap1 signaling rather than an ar-
tifact due to the use of a speciﬁc TCR-transgenic model, we additionally
quantiﬁed the frequency of MOG-speciﬁc T cells in wildtype (WT) an-
imals 10 days after immunization with MOG peptide using peptide-
MHC tetramers (Sabatino et al., 2008, 2011). Staining with MOG38-
49-IAb or hCLIP103–117 IAb tetramers as a negative control indicates a
signiﬁcantly decreased frequency of MOG-autoreactive CD4+ T cellsctive T cell population without affecting cell viability. Splenocytes from naive (A) and
, anti-CD3/CD28 antibodies and MOG peptide for 3 days. 7-AAD was used to enumerate
om the surviving viable T cell population (A–B). Splenocytes from 2D2+RapV12- and
anti-CD4, anti-Vβ11, anti-CD62L and anti-CD44 antibodies. The frequency of effector
within the Vβ11+CD4+ T lymphocyte compartment was analyzed by ﬂow cytometry.
).
Fig. 5. The MOG-autoreactive effector and memory T cell compartments are signiﬁcantly reduced in RapV12 animals. Splenocytes from 2D2+RapV12- and 2D2+RapV12+ mice
immunized with MOG peptide (A–B) or naive mice (C–D) were collected and stained with anti-CD3, anti-CD4 and anti-Vβ11 antibodies. The frequency of Vβ11+CD4+ (A, C) and
CD4+ (B, D) T lymphocytes was compared using Mann–Whitney test. Lymph node cells in WT and RapV12+ mice immunized with MOG peptide were collected 10 days after
immunization. CD4+ T lymphocytes were puriﬁed and the enriched fraction was stained with anti-CD3, anti-CD4, anti-CD44 and anti-CD62L antibodies, and MOG38-49-IAb to
identify antigen-speciﬁc cells. The percentages of tetramer positive T cells in the lymph nodes (E) and within the effector and memory populations (F) were compared using
Mann Whitney test (*p-value≤0.05).
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percentages of MOG-autoreactive T cells were also decreased in the
CD44+ effector and central memory T cells (p=0.04, Fig. 5F). Taken
together, these experiments indicate that sustained Rap1 signaling
reduces the size of the pool of autoreactive T cells.
3.5. Sustained Rap1 activation decreases mortality during experimental
autoimmune encephalomyelitis
Aswepreviously observed that RapV12micewere protected fromCIA
(Abreu et al., 2010), we next assessed whether the qualitative and quan-
titative effects of sustained Rap1 signaling on the MOG-autoreactive T
cells translated in an altered disease incidence or severity in EAE. We
ﬁrst evaluated clinical disease in the 2D2 animals, where the strong bias
of the T cell repertoire towards autoreactivity leads to rapid onset and
very severe EAE upon MOG immunization (Bettelli et al., 2003). Com-
parison of the 2D2+RapV12+ double transgenic mice and 2D2+
RapV12- single transgenic littermate controls showed a slightly but
not signiﬁcantly decreased severity and incidence of EAE in the pres-
ence of RapV12, resulting in a signiﬁcantly increased survival of these
animals (p=0.04, Fig. 6A–C). As clinical effects may be blurred in this
TCR transgenic model due to the high severity of disease, we repeated
these experiments in RapV12 mice versus WT littermate controls. In
these experiments, the overall disease scores in the WT mice were
lower, with an incidence of almost 60% and a mean disease score of
2.3 in the affected mice, resulting in an overall disease score of approx-
imately 1.3 (Fig. 6D). Againwe observed a clear trend towards decreaseddisease severity (p=0.070) (Fig. 6D) and incidence (p=0.085) (Fig. 6E)
in the RapV12 mice. Accordingly, the mortality rate was signiﬁcantly
lower in the RapV12 mice than in WT littermates (p=0.02, Fig. 6F). In
conclusion, these data indicate that sustained Rap1 signaling in T cells
decreased mortality during MOG-induced EAE.
4. Discussion
Rap1 is an intracellular small GTPase, which is activated in T cells
following TCR ligation, chemokine stimulation, and engagement of
adhesion proteins. To date, regulation of the quality of T cell immune
responses by Rap1 has been attributed to the proposed capacity of ac-
tive Rap1 to suppress Ras-dependent MAP kinase proliferative path-
ways (Boussiotis et al., 1997). In mice lacking Spa-1, a GAP for Rap1,
an age-dependent decrease in T cell proliferation and cytokine pro-
duction in response to anti-CD3/CD28 antibodies and recall antigen
stimulation is observed (Ishida et al., 2003). Similar defective T cell
responses are reported in transgenic mice expressing constitutively
active Rap1E63 in the T cell compartment (Li et al., 2005). Conversely,
decreasing Rap1 function by transgenic overexpression of RapGAP I in
the T cell compartment leads to an age-dependent accumulation of T
cells in lymphoid organs which display surface markers indicative of
immune activation (Dillon et al., 2005). Additionally, there is substan-
tial evidence that activation of Rap1 regulates T cell functional re-
sponses by coordinating the activation of integrins required for T
cell chemotactic responses and trafﬁcking and for stable conjugation
with APCs (Burbach et al., 2007; Menasche et al., 2007). In vivo and
Fig. 6. Sustained Rap1 signaling decreases disease severity and mortality in MOG-induced experimental autoimmune encephalomyelitis. 2D2+RapV12+ and 2D2+RapV12-
transgenic mice (A–C) and RapV12 and WT mice (D–F) were immunized with MOG peptide. EAE development was monitored for 30 days and neurological signs of disease
were scored daily. At the end of the experiment, the clinical scores in time were compared between groups (A, D). The incidence of EAE (B, E) and the survival proportions
(C, F) were calculated per group and compared using the Grehan–Breslow–Wilconox test (*p-value≤0.05).
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association of Rap1 with the adaptor proteins RapL (regulator of ad-
hesion and cell polarization enriched in lymphoid tissues), SKAP1
(src kinase-associated phosphoprotein 1) and ADAP (adhesion and
degranulation-promoting adaptor protein), is required for clustering
of T cell integrins, T cell homing to secondary LN, and productive ar-
rest of T cells with APCs (Katagiri et al., 2003, 2004, 2006; Ebisuno
et al., 2010; Raab et al., 2010). Accordingly, transgenic expression of
constitutively active RapE63 or hypermorphic RapV12 stimulates T
cell integrin-dependent adhesion, while Rap1A−/−T cells display par-
tial defects in TCR and chemokine‐induced adhesion (Sebzda et al.,
2002; Li et al., 2005).
We have previously demonstrated that sustained T cell Rap1 acti-
vation is protective in experimental T cell-mediated autoimmune dis-
ease, but it remains largely unknown how the different effects of
Rap1 on T cell interactions with APCs, proliferation and homing im-
pact upon autoreactive T cells and modulate autoimmune disease in
vivo (Abreu et al., 2010). Using 2D2 TCR and RapV12 double transgen-
ic mice, we were able to analyze the qualitative and quantitative im-
pact of Rap1 signaling on MOG-autoreactive T cells and to assess how
this translates into modulation of EAE. We considered possible effects
of sustained T cell Rap1 activation on auto-reactive T cell proliferative
responses, cytokine production, and survival, and found that each of
these parameters was enhanced in mice expressing RapV12. Howev-
er, this was offset by a decrease in the total numbers of autoreactive T
cells, both on the 2D2 TCR transgenic background and in mice ex-
pressing endogenous TCR repertoires. This reduction in autoreactive
T cell numbers appears clinically important, as despite the ability of
RapV12 to enhance intrinsic T cell responses to MOG, 2D2+RapV12+
and RapV12+ mice displayed enhanced survival during EAE.
In our analyses, we ﬁrst considered the possibility that RapV12
may dampen antigen-speciﬁc T cell proliferative responses or induce
anergy. Rap1-GTP levels are elevated in anergic T cells, and transgenic
overexpression of constitutively active Rap1E63 reduces CD4+ T cellIL-2 production and proliferation induced by anti-CD3/CD28 stimula-
tion and during antigen recall (Boussiotis et al., 1997; Li et al., 2005).
However, this is not observed in RapV12 mice and, in contrast,
antigen-speciﬁc proliferation at low antigen concentrations is enhanced
(Sebzda et al., 2002). This difference between Rap1E63 and RapV12mice
is attributed to the ability of RapV12 to still cycle between the active and
inactive state, albeit at a reduced level, and the relative overexpression of
Rap1E63 compared to RapV12. In our analyses of RapV12 mice during
CIA,we also failed to observe defective polyclonal proliferative responses
to anti-CD3/CD28 stimulation (Abreu et al., 2010). Here, we conﬁrmed
and extended these ﬁndings by demonstrating that RapV12 conferred
a proliferative advantage not only upon polyclonal anti-CD3/CD28 stim-
ulation but also upon MOG stimulation of the autoreactive T cells. This
proliferative advantage was observed both during primary and recall re-
sponses to MOG and was associated with increased IL-2 production and
upregulation of ICOS. Cumulatively, these data indicate that sustained
Rap1 activation does not induce anergy but rather intrinsic hyper-
reponsiveness of the autoreactive T cells in this model.
A second possible effect of sustained Rap1 signaling which we stud-
ied was the modulation of cytokine production by autoreactive T cells.
We previously observed that RapV12mice displayed a selective impair-
ment in TNFα production by CD8+ LNT cells during the early phases of
CIA, possibly due to clonal exhaustion of speciﬁc T cell subsets (Abreu et
al., 2010). Here, speciﬁc analysis of the autoreactive CD4+ cells did not
show any decrease for IFNγ and IL-17, which are the major pathogenic
cytokines in EAE. For TNFα, the role of which remains more controver-
sial in EAE (Ruddle et al., 1990; Klinkert et al., 1997; Liu et al., 1998; Dal
Canto et al., 1999), production was increased rather than decreased in
the autoreactive T cell pool. Also, expression levels of PD-1, a marker
of clonal exhaustion, were equivalent between 2D2+RapV12+ and
2D2+RapV12- MOG-speciﬁc T cells, and re-challenge of these
autoreactive T cells with MOG peptide in vitro revealed no proliferative
impairment which usually precedes loss of TNFα expression in viral
models of clonal exhaustion (Wherry, 2011). These data indicate that
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EAE, as the T cells maintain their ability to produce pathogenic cyto-
kines. The apparent paradox between CIA and EAE models emphasizes
that the biological effects of sustained Rap1 activation are certainly not
restricted to the autoreactive T cell pool, as assessed in the present
study of EAE. This concept is very important as not only the pathogenic
autoreactive T cells but also other T cell populations such as CD8+ T
cells and regulatory T cells will ultimately contribute to determine the
clinical disease severity and phenotype.
Besides the impact on the quality of the autoreactive T cell responses,
we also considered the possibility that Rap1 activation could affect the
size of the autoreactive T cell pool. A ﬁrst reason to propose a quantita-
tive effect is that the proliferative advantage of T cell lines expressing ac-
tive Rap1 is offset by enhanced AICD (Katagiri et al., 2002). However, we
could obtain no evidence that this happens during autoimmune disease
in the 2D2+RapV12+mice as 2D2+RapV12+ T cells instead showed
a survival advantage compared to 2D2+RapV12- T cells following
ex vivo stimulation with anti-CD3/CD28 antibodies or MOG peptide.
Additionally, we observed an enhanced accumulation of effector and
memory autoreactive T cells upon MOG immunization in the 2D2+
RapV12+ animals. These results are similar to the recently reported ob-
servations that the Rap1 effector ADAP augments T cell proliferation and
survival in response to limiting antigen concentration in vivo (Mueller
et al., 2007). A second reason to propose a quantitative effect is that
Ras and Rap1 activation is detected in thymocytes undergoing both
positive and negative selection (Amsen et al., 2000). Genetic deletion
or inactivation of RasGRP1 dampens, but does not completely abrogate,
TCR-dependent Ras activation (Priatel et al., 2002; Layer et al., 2003).
While peripheral T cell numbers and TCR-dependent proliferative re-
sponses are greatly reduced, RasGRP1 defects lead to T cell-mediated au-
toimmunity resembling SLE. This is attributed to abnormal thymic
selection, where weakened Ras pathways fail to deliver signals sufﬁcient
for negative selection of thymocytes bearing autoreactive TCRs. RapV12,
possibly via integrin-dependentmechanisms, can promote positive selec-
tion of thymocyteswith lowantigen afﬁnity (Sebzda et al., 2002). By anal-
ogy with RasGRP-deﬁciency, Rap1 activation could possibly strengthen
thymocyte interactions with APCs to promote negative selection of
autoreactive T cells. Consistent with this hypothesis, we found that the
size of the MOG-autoreactive T cell pool was reduced by approximately
one third in TCR transgenic animals expressing RapV12. A similar albeit
smaller effectwas observedby tetramer analysis in animalswith anormal
TCR repertoire, excluding a bias due to the speciﬁc TCR receptor of the
2D2 mice. Preliminary experiments failed to reveal gross abnormalities
in thymocyte developmental subset frequencies in 2D2+RapV12+
mice (own unpublished observations). However, as the ability of Rap1
to inﬂuence thymic selection is sensitive to TCR afﬁnity, subtle differences
not identiﬁed in our studies may eventually impact upon the size of the
peripheral autoreactive T cell pool (Sebzda et al., 2002). Our observation
that the 2D2 autoreactive pool is reduced not only in immunized but
also in MOG-naïve animals supports the hypothesis that Rap1 signaling
could affect central tolerance (Minato et al., 2007). Together with the re-
cent observation that pathology in EAE is mainly caused by low afﬁnity
tetramer-negative T cells (Sabatino et al., 2011), these data warrant fur-
ther detailed investigation of how Rap1 affects positive and negative se-
lection of T cells, and their maintenance in the periphery, depending on
the TCR afﬁnity for autoantigen.
Our data indicate that sustained Rap1 signaling has complex qual-
itative and quantitative impacts on autoreactive T cells, raising the
key question as to how these multiple effects integrate in vivo to
modulate autoimmune disease. In line with our previous CIA data,
we demonstrated here that RapV12 attenuates EAE, even though it
should be noted that the clinical effect was probably more modest
than in the CIA model (Abreu et al., 2010). In the 2D2 model, this par-
tial protection was only signiﬁcant for survival but not for incidence
or severity of EAE. This is probably due to the fact that the disease sus-
ceptibility conferred by the TCR background is too large to allowmodulation of clinical disease. Accordingly, the protection of the
RapV12 mice was clearer on a WT TCR background. In this regard, it
is noteworthy that T cell RapV12-mediated attenuation of disease se-
verity in EAE was not as complete as observed in CIA. This is likely due
to the speciﬁc suppression of auto-antibodies in CIA and the pro-
nounced requirement for anti-collagen antibodies in this model
(Abreu et al., 2010; Bevaart et al., 2010). EAE is less dependent on auto-
antibodies and we did not observe signiﬁcant modulation of the anti-
MOG antibodies by RapV12 (our own unpublished data). Secondly, the
previously mentioned effect of RapV12 on TNFα production by T cells
is thought to bemore relevant for synovial inﬂammation in autoimmune
arthritis than for CNS damage in EAE. Thirdly, RapV12 may also affect
other aspects of (autoimmune) T cell biology which were not analyzed
in detail in the present study. Of particular interest is the recent evidence
that signaling pathways downstream of Ras GTPases can regulate the
temporal expression of adhesion molecules involved in T cell trafﬁcking
(Mueller et al., 2007; Sinclair et al., 2008). Certainly in EAE where
autoreactive T cells need to cross the blood–brain barrier and home to
the central nervous system, future studies will be needed to determine
if therapeuticmanipulation of Rap1 activity can alter recruitment and re-
tention of autoreactive T cells at the site of inﬂammation.
In conclusion, the present studyprovides evidencedemonstrating that
Rap1 signaling impacts upon autoimmune T cells at different levels, and
conﬁrms the concept that sustained Rap1 activation dampens T cell-
mediated autoimmunity. Therefore, Rap1 signaling forms an attractive
target for pharmacological modulation of pathogenic T cells in immune-
mediated inﬂammatory diseases.
Supplementary related to this article can be found online at http://
dx.doi.org/10.1016/j.jneuroim.2012.05.012.
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